ArticleViruses2025
Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study.
Flavia Petrucci, Chiara Pellicano, Francesco Cogliati Dezza, Serena Valeri, Sara Covino, Francesco Iannazzo, Francesca Infante, Antonietta Gigante, Federica Sacco, Agnese Viscido and 5 more
Abstract read
In one paragraphArticle in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Flavia PetrucciDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0009-0008-1715-9532 Chiara PellicanoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185 Rome, Italy.ORCID 0000-0003-1077-4846 Francesco Cogliati DezzaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-5657-7373 Serena ValeriDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Sara CovinoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Francesco IannazzoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185 Rome, Italy.
Francesca InfanteDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Antonietta GiganteDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185 Rome, Italy.ORCID 0000-0002-2015-765X Federica SaccoMicrobiology and Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Agnese ViscidoMicrobiology and Virology Laboratory, Department of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Alessandra IacovelliDepartment of Public Health and Infectious Diseases, Pulmonology Respiratory and Critical Care Unit, Policlinico Umberto I Hospital Rome, 00161 Rome, Italy.ORCID 0000-0002-7103-7842 Edoardo RosatoDepartment of Translational and Precision Medicine, Sapienza University of Rome, Viale Dell'Università 37, 00185 Rome, Italy.ORCID 0000-0002-7417-8093 Paolo PalangeDepartment of Public Health and Infectious Diseases, Pulmonology Respiratory and Critical Care Unit, Policlinico Umberto I Hospital Rome, 00161 Rome, Italy.
Claudio Maria MastroianniDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-1286-467X Alessandra OlivaDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-0832-7975 Funding
Sapienza University of Rome AR123188B452BF8A
6 · The paper itselfAbstract
Patients with hematological malignancies (HMs) are at higher risk of severe COVID-19 and secondary infections, which further complicate their outcomes. This study evaluated the impact of secondary infections (SIs) on mortality in hospitalized HM patients with SARS-CoV-2 infection and identified risk factors associated with SIs. We included 217 patients with HMs and COVID-19 admitted to a tertiary hospital in Rome, from April 2020 to September 2022. SIs occurred in 44.2% of patients, with bloodstream infections (42.7%) and respiratory infections (30.5%) being most frequent; among the latter, COVID-19-associated pulmonary aspergillosis (CAPA) was observed in 41.4% of cases. Viral reactivations, predominantly CMV, occurred in 9.2% of patients. The overall mortality rate was 29%, with higher mortality observed in patients with SIs (47.4% vs. 14.7%,
Indexed as
COVID-19Hematologic NeoplasmsAdultAgedAged, 80 and overFemaleHospitalizationHumansMaleMiddle AgedRisk FactorsSARS-CoV-2COVID-19COVID-19-associated pulmonary aspergillosis (CAPA)hematological malignanciesmortalitySARS-CoV-2secondary infectionsviral reactivation
Identifiers
PMID40007029
PMCPMC11861615
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390